XELODA
(capecitabine) is a nucleoside metabolic inhibitor indicated for:
*Colorectal Cancer
•
adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen.
•
perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy.
•
treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen.
*Breast Cancer
•
treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline-or taxane-containing chemotherapy is not indicated.
•
treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy.
*Gastric, Esophageal, or Gastroesophageal Junction Cancer
•
treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen. (1.3)
●
treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen.
*Pancreatic Cancer
• adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
